Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes Journal Article
| Authors: | Bailey, K.; Pandit-Taskar, N.; Humm, J. L.; Zanzonico, P.; Gilheeney, S.; Cheung, N. K. V.; Kramer, K. |
| Article Title: | Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes |
| Abstract: | PurposeWe explored the use of intraventricular I-131-Omburtamab targeting B7-H3 in patients with ETMR.MethodsPatients were enrolled in an IRB approved, phase 1, 3+3 dose escalation trial. Patients with CNS disease expressing the antibody target antigen B7-H3 were eligible. We report on a cohort of three patients with ETMR who were enrolled on the study. Three symptomatic children (ages 14 months, 3 and 3.5years) had large parietal masses confirmed to be B7-H3-reactive ETMR. Patients received 2mCi I-131-Omburtamab as a tracer followed by one or two therapeutic I-131-Omburtamab injections. Dosimetry was based on serial CSF, blood samplings and region of interest (ROI) on nuclear scans. Brain and spine MRIs and CSF cytology were done at baseline, 5 weeks after I-131-Omburtamab, and approximately every 3months thereafter. Acute toxicities and survival were noted.ResultsPatients received surgery, focal radiation, and high dose chemotherapy. Patients 1 and 2 received I-131-Omburtamab (80 and 53mCi, respectively). Patient 3 had a local recurrence prior to I-131-Omburtamab treated with surgery, external beam radiation, chemotherapy, then I-131-Omburtamab (36mCi). I-131-Omburtamab was well-tolerated. Mean dose delivered by I-131-Omburtamab was 68.4cGy/mCi to CSF and 1.95cGy/mCi to blood. Mean ROI doses were 230.4 (ventricular) and 58.2 (spinal) cGy/mCi. Patients 1 and 2 remain in remission 6.8years and 2.3years after diagnosis, respectively; patient 3 died of progressive disease 7months after therapy (2years after diagnosis).Conclusions(131)I-Omburtamab appears safe with favorable dosimetry therapeutic index. When used as consolidation following surgery and chemoradiation therapy, I-131-Omburtamab may have therapeutic benefit for patients with ETMR. |
| Keywords: | radioimmunotherapy; children; abundant neuropil; etmr; embryonal tumor with multilayered rosettes; i-131-omburtamab; i-131-8h9 |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 143 |
| Issue: | 1 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Date Published: | 2019-05-01 |
| Start Page: | 101 |
| End Page: | 106 |
| Language: | English |
| ACCESSION: | WOS:000465615000011 |
| DOI: | 10.1007/s11060-019-03139-6 |
| PROVIDER: | wos |
| PUBMED: | 30879172 |
| PMCID: | PMC7416633 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work